Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement

Core Points - Adial Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000 [1][2] - The CEO of Adial expressed that regaining compliance is a significant step in reinforcing investor confidence and supporting the company's long-term growth strategy [2] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders [2] - The lead investigational product, AD04, is a serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients [2] - The ONWARD™ pivotal Phase 3 clinical trial for AD04 showed promising results in reducing drinking among heavy drinkers without significant safety or tolerability concerns [2] - AD04 may also have potential applications in treating other addictive disorders such as Opioid Use Disorder, gambling, and obesity [2]